Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD80 (B7.1) is a type I transmembrane glycoprotein expressed on antigen-presenting cells (APCs) and activated T cells. It functions as a co-stimulatory molecule crucial for T-cell activation and immune regulation. CD80 interacts with CD28 to deliver a stimulatory signal and with CTLA-4 (CD152) to deliver an inhibitory signal, thereby modulating immune responses. This pathway plays a critical role in initiating primary immune responses, maintaining peripheral tolerance, and regulating autoimmunity through immune checkpoint inhibition mechanisms.
Modulation of T-cell activation via CD28 and CTLA-4 interaction; immune checkpoint inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B7.1 protein (CD80) (None).